Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

Chinese authorities detained AstraZeneca’s former China head Leon Wang last year and revealed a probe into potential illegal drug importation early this year. Against that backdrop, AstraZeneca ...